In this phase 3b open-label, randomised, controlled trial, 751 adult participants with obesity, but without type 2 diabetes, in a 1:1 ratio received tirzepatide maximum tolerated dose (10mg or 15mg) or semaglutide maximum tolerated dose (1.7mg or 2.4mg) subcutaneously once weekly for 72 weeks
Li W, Yu S-W, Kong A-NT
Follow the tirzepatide reconstitution chart carefully, and use bacteriostatic water for reconstitution

WATER, ETHYLHEXYL METHOXYCINNAMATE, BUTYLENE GLYCOL, ETHYLHEXYL SALICYLATE, OCTOCRYLENE, BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE, BUTYL METHOXYDIBENZOYLMETHANE, DIPROPYLENE GLYCOL, NIACINAMIDE, SQUALANE, C14-22 ALCOHOLS, 1,2-HEXANEDIOL, POLYGLYCERYL-2 STEARATE, PROPANEDIOL, HYDROXYACETOPHENONE, GLYCERYL STEARATE, STEARYL ALCOHOL, C12-20 ALKYL GLUCOSIDE, TROMETHAMINE, CENTELLA ASIATICA EXTRACT, CARBOMER, MELALEUCA ALTERNIFOLIA (TEA TREE) EXTRACT, HIPPOPHAE RHAMNOIDES FRUIT EXTRACT, VITIS VINIFERA (GRAPE) FRUIT EXTRACT, ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER, UNCARIA SINENSIS EXTRACT, GLYCERIN, ADENOSINE, DISODIUM EDTA, ORYZA SATIVA (RICE) BRAN EXTRACT, HYDROGENATED PHOSPHATIDYLCHOLINE, CAPRYLIC/CAPRIC TRIGLYCERIDE, SODIUM HYALURONATE, GLUCOSE, HYDROLYZED COLLAGEN, SUCROSE STEARATE, GLUTATHIONE, CYCLODEXTRIN, CETEARYL ALCOHOL, CAPRYLYL GLYCOL, BETA-GLUCAN, CAPRYLHYDROXAMIC ACID, ETHYLHEXYLGLYCERIN, ASIATIC ACID, ASIATICOSIDE, MADECASSIC ACID, MADECASSOSIDE, TROPOLONE, HYALURONIC ACID, POTASSIUM HYALURONATE *** Ingredients are subject to change at the manufacturer's discretion
